In short
Tretinoin is being studied in clinical trials for several different conditions, including acne, melanoma, acute promyelocytic leukemia, and head and neck cancer. These trials look at safety, effectiveness, and key outcomes such as survival, response, and skin lesion improvement in different patient groups.
Key points
- Tretinoin is being studied in trials for both acne and several cancer types. The acne studies are Phase 3 trials that compare Tretinoin-containing gels with reference products or placebo and measure changes in lesion counts. The cancer studies are mostly Phase 1 or Phase 2 trials that test Tretinoin with other treatments in melanoma, leukemia, head and neck cancer, and oligometastatic solid cancer. The main goals include safety, response to treatment, overall survival, event-free survival, and protection from radiation-related lymphopenia. Some studies include adults, while one leukemia trial includes children and adolescents. These trials show that Tretinoin is being tested in very different patient groups and treatment settings.
Trial overview
The trial data show that Tretinoin is being studied in very different diseases, not just one condition. The main areas are acne, melanoma, acute myeloid leukemia, acute promyelocytic leukemia, oligometastatic solid cancer, and head and neck squamous cell carcinoma.
These studies include both interventional trials, where researchers assign treatments, and different comparison designs such as placebo-controlled and active-controlled studies. The trials range from early Phase 1 research to larger Phase 3 studies.
Acne studies
Several Phase 3 trials are focused on acne, including acne vulgaris and papulopustular acne. In these studies, Tretinoin is tested in gel form together with clindamycin, and the results are compared with a reference product or with a vehicle, which is a look-alike gel without the active medicine.
One completed multicenter trial compared clindamycin + tretinoin/Verisfield gel with Acnatac®/Meda gel and placebo in 600 people with acne vulgaris. Another authorised Phase 3 trial is studying a similar clindamycin and Tretinoin gel in 675 patients with papulopustular acne.
The main acne outcomes are changes in facial lesion counts over 12 weeks, including inflammatory lesions such as papules and pustules, and non-inflammatory lesions such as open and closed comedones. These outcomes help show whether the treatment reduces visible acne spots over time.
Cancer studies
Most cancer trials with Tretinoin are early-phase studies that test it with other treatments.
In melanoma, Tretinoin appears in Phase 1 studies for stage IIIB, IIIC, and IIID melanoma and for PD-1 refractory melanoma, which means melanoma that no longer responds to PD-1 treatment. These studies combine Tretinoin with drugs such as pembrolizumab, lenvatinib, vibostolimab, quavonlimab, and other investigational agents.
The melanoma trials mainly measure adverse events, treatment stopping because of side effects, and objective response rate, which means how many patients have a measurable tumor response. One study also looks at pathological complete response, meaning no cancer is found in the tissue after treatment.
In leukemia, one Phase 3 trial in newly diagnosed acute myeloid leukemia compares all-trans retinoic acid, also called ATRA, with placebo when added to decitabine and venetoclax, and its main endpoint is overall survival. Another study in children and adolescents with acute promyelocytic leukemia tests ATRA with arsenic trioxide, and in some higher-risk patients also with gemtuzumab ozogamicin.
The pediatric leukemia trial measures event-free survival, which includes failure to reach remission, relapse, or death, and it aims to understand results over several years after diagnosis. This makes it a long-term outcome study, not only a short safety check.
In head and neck cancer, a Phase 3 trial studies Tretinoin, also listed as all-trans retinoic acid, together with radiotherapy strategies in patients with lateralised oropharyngeal, laryngeal, and hypopharyngeal squamous cell carcinoma. Its main endpoint is event-free survival.
Another Phase 1 trial in oligometastatic solid cancer studies Tretinoin with stereotactic body radiotherapy, which is a highly focused form of radiation treatment. This study has two main goals: safety in the first part and protection against radiation-related lymphopenia, which means a drop in lymphocytes, a type of white blood cell.
Study designs and phases
The acne studies are designed as multicenter, randomized, double-blind, parallel trials, which are strong methods for comparing treatments fairly. They also use active controls and placebo controls to show whether the Tretinoin-containing gel works better than comparison treatments.
The cancer studies use different early and late development phases based on the question being asked. Phase 1 trials focus on safety and tolerability, while Phase 2 and Phase 3 trials study whether the treatment helps patients and whether the benefit is strong enough for larger testing.
Main endpoints measured
The acne studies measure the percent change in inflammatory and non-inflammatory lesion counts from baseline to Week 12. Baseline means the first measurement before treatment starts.
The melanoma studies measure safety endpoints such as adverse events and dose-limiting toxicity, plus response outcomes like objective response rate and pathological complete response. Dose-limiting toxicity means a side effect serious enough to limit treatment in the early part of a study.
The leukemia and head and neck cancer studies focus on survival outcomes, especially overall survival and event-free survival. The oligometastatic solid cancer study adds a special safety outcome for lymphopenia after treatment.
Who participates in these trials
Trial participants are chosen based on the disease being studied.
- People with acne vulgaris or papulopustular acne join the skin studies, which compare Tretinoin-containing gels with reference treatment or vehicle.
- Adults with stage IIIB, IIIC, IIID, or PD-1 refractory melanoma join the melanoma trials, where Tretinoin is tested in combination with other cancer medicines.
- Adults with newly diagnosed acute myeloid leukemia join the DECIDER-2 trial if they are not eligible for induction chemotherapy, which is the standard intensive first treatment.
- Children and adolescents with acute promyelocytic leukemia join the pediatric study, which tests ATRA-based treatment plans.
- People with lateralised oropharyngeal, laryngeal, or hypopharyngeal squamous cell carcinoma join the head and neck cancer trial, and people with oligometastatic solid cancer join the radiotherapy study.
Key patient takeaways
The trial data show that Tretinoin is being studied in both common skin disease and several serious cancers.
For acne, the main question is whether Tretinoin-containing gels reduce lesion counts better than reference products or placebo. For cancer, the main questions are safety, response, survival, and whether Tretinoin can help when added to other treatments.
Across the studies, the evidence base includes randomized Phase 3 acne trials and smaller early-phase cancer trials, giving a broad view of how Tretinoin is being tested in modern clinical research.